Balyasny Asset Management LLC Xeris Biopharma Holdings, Inc. Transaction History
Balyasny Asset Management LLC
- $57.8 Billion
- Q1 2025
A detailed history of Balyasny Asset Management LLC transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 34,454 shares of XERS stock, worth $170,202. This represents 0.0% of its overall portfolio holdings.
Number of Shares
34,454
Previous 17,153
100.86%
Holding current value
$170,202
Previous $58,000
225.86%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding XERS
# of Institutions
204Shares Held
84.7MCall Options Held
132KPut Options Held
69.4K-
Black Rock Inc. New York, NY10.3MShares$51 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.11MShares$40.1 Million0.0% of portfolio
-
Morgan Stanley New York, NY4.29MShares$21.2 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.41MShares$16.8 Million0.0% of portfolio
-
State Street Corp Boston, MA3.33MShares$16.4 Million0.0% of portfolio
About Xeris Biopharma Holdings, Inc.
- Ticker XERS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 135,956,992
- Market Cap $672M
- Description
- Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...